In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Saver's Bonus Act of 2007''.

SEC. 2. FINDINGS.

    Congress finds the following:
            (1) According to the Department of Commerce, Americans are 
        currently saving less than 1 percent of their disposable 
        income.
            (2) According to the Federal Reserve's 2004 Survey of 
        Consumer Finances, 17 percent of all households have zero or 
        negative net worth, while 30 percent have net worth of less 
        than $10,000.
            (3) According to the Federal Reserve's 2004 Survey of 
        Consumer Finances, 11 percent of households do not have a 
        checking account and 9 percent do not have a transaction 
        account of any kind.
            (4) According to the Retirement Security Project, in 2004 
        more than half of all households had zero savings in an 
        employer-based 401(k)-type plan or tax-preferred savings plan 
        account.
            (5) It is in the economic interests of the United States to 
        promote savings among all members of society, regardless of 
        income.

SEC. 3. SAVER'S BONUS.

    (a) In General.--The Secretary of the Treasury shall develop a 
program to match deposits made by qualifying low-income individuals 
into designated savings products.
    (b) Qualifying Low-Income Individuals.--For purposes of this Act, 
the term ``qualifying low-income individual'' means any individual 
determined by the Secretary of the Treasury to be eligible for the 
saver's bonus under this Act.
    (c) Designated Savings Products.--For purposes of this Act, the 
term ``designated savings product'' means any savings product, 
including--
            (1) qualified retirement plans (as defined in section 
        4974(c)) of such Code,
            (2) qualified tuition programs under section 529 of such 
        Code,
            (3) Coverdell education savings accounts under section 530 
        of such Code,
            (4) United States savings bonds,
            (5) certificates of deposits with durations of at least 6 
        months, and
            (6) other types of savings products considered appropriate 
        by the Secretary of the Treasury for the purposes of this Act.
    (d) Saver's Bonus Program.--The program established under 
subsection (a) shall provide that--
            (1) qualifying low-income individuals who direct their 
        Federal income tax refund (in its entirety or a portion 
        thereof) be deposited into any designated savings product shall 
        be eligible for a dollar-for-dollar match or saver's bonus to 
        be deposited directly in any designated savings product,
            (2) qualifying low-income individuals who claim (when 
        filing a Federal income tax return) to have deposited funds 
        into any designated savings product during the course of the 
        tax year shall be eligible for a saver's bonus to be deposited 
        directly into any designated savings product, and
            (3) the saver's bonus--
                    (A) shall equal $500 for qualifying low-income 
                individuals who are eligible for the earned income 
                credit under section 32 of such Code and shall be 
                phased out (but not below zero) for such individuals 
                whose earned income exceeds 120 percent of the earned 
                income threshold at which such eligibility ceases,
                    (B) shall be indexed for inflation every 5 years, 
                and
                    (C) shall be considered a refundable credit for 
                purposes of the Internal Revenue Code of 1986.
    (e) Conforming Amendment Regarding Funding of Saver's Bonus.--
Section 1324(b)(2) of title 31, United States Code, is amended by 
inserting ``or enacted by the Saver's Bonus Act of 2007,''.
    (f) Effective Date.--The program under, and amendment made by, this 
section shall be effective with respect to Federal income tax returns 
for taxable years beginning after December 31, 2008.

SEC. 4. OPENING OF ACCOUNTS ON FEDERAL INCOME TAX RETURNS TO FACILITATE 
              SAVINGS.

    (a) Notification of Option.--
            (1) In general.--The Commissioner of Internal Revenue shall 
        notify qualifying low-income individuals who qualify for a 
        Federal income tax refund but fail to provide an ACH direct 
        deposit number on their Federal income tax return that they 
        have the option of an electronic direct deposit and that they 
        may be eligible for the saver's bonus program under section 3 
        if they deposit a refund or a portion of their refund in any 
        designated savings product.
            (2) Method of notification.--The notification under 
        paragraph (1) shall be made through--
                    (A) a public awareness program undertaken by the 
                Secretary of the Treasury, in concert with the 
                Commissioner of the Internal Revenue and others as 
                necessary, at least 6 months before January 2009, and
                    (B) the inclusion of such a notice in the 
                instruction material for any Federal income tax return.
    (b) Establishment of Designated Account Program.--The Secretary of 
the Treasury shall develop, in consultation with the Federal Management 
System, a program to minimize the delivery of non-electronic Federal 
income tax refunds by depositing refunds electronically to an account 
held by a depository institution. This program shall include--
            (1) provisions for such tax refunds to be deposited into a 
        designated account,
            (2) establishment of account parameters with respect to 
        minimum balance requirements and limitations on overdrafts, 
        overdraft fees, and other requirements,
            (3) establishment of means for the taxpayer to access the 
        account electronically or through a payment card, and
            (4) provisions to allow taxpayers to open an account with 
        their Federal income tax refunds through financial service 
        providers, so long such account is held at a depository 
        institution that is insured under the Federal Deposit Insurance 
        Act (12 U.S.C. 1811 et seq.).
    (c) Effective Date.--The notification under subsection (a) and the 
program under subsection (b) shall be effective with respect to Federal 
income tax returns for taxable years beginning after December 31, 2008.

SEC. 5. PURCHASE OF SAVINGS BONDS ON FEDERAL INCOME TAX RETURNS.

    (a) Notification of Option.--The Commissioner of Internal Revenue 
shall notify individual taxpayers that they have the option of 
purchasing United States savings bonds when they file their Federal 
income tax returns and that they may be eligible for the saver's bonus 
program under section 3. Such notification shall be included in the 
instruction material for any Federal income tax return.
    (b) Establishment of Savings Bond Purchase Program.--The Secretary 
of the Treasury shall develop, in consultation with a task force, a 
program for the purchase by individual taxpayers of United States 
savings bonds on their Federal income tax returns.
    (c) Effective Date.--The notification under subsection (a) and the 
program under subsection (b) shall be effective with respect to Federal 
income tax returns for taxable years beginning after December 31, 2008.

A: Saver's Bonus Act of 2007 [sic] - Directs the Secretary of the Treasury to develop programs to: (1) match deposits made by low-income individuals into certain savings accounts (saver's bonus); (2) deposit tax refunds electronically into savings accounts; and (3) allow individual taxpayers to purchase U.S. savings bonds on their federal income tax returns.

Requires the Commissioner of the Internal Revenue Service (IRS) to notify low-income taxpayers of their eligibility for the saver's bonus and of their options under this Act.
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Security Contractor Accountability 
Act of 2007''.

SEC. 2. LEGAL STATUS OF CONTRACT PERSONNEL.

    (a) Clarification of the Military Extraterritorial Jurisdiction 
Act.--
            (1) Inclusion of contractors.--Subsection (a) of section 
        3261 of title 18, United States Code, is amended--
                    (A) by striking ``or'' at the end of paragraph (1);
                    (B) by striking the comma at the end of paragraph 
                (2) and inserting ``; or''; and
                    (C) by inserting after paragraph (2) the following:
            ``(3) while employed under a contract (or subcontract at 
        any tier) awarded by any department or agency of the United 
        States, where the work under such contract is carried out in an 
        area, or in close proximity to an area (as designated by the 
        Department of Defense), where the Armed Forces is conducting a 
        contingency operation,''.
            (2) Definition.--Section 3267 of title 18, United States 
        Code, is amended by adding at the end the following:
            ``(5) The term `contingency operation' has the meaning 
        given such term in section 101(a)(13) of title 10.''.
    (b) Department of Justice Inspector General Report.--
            (1) Report required.--Not later than 180 days after the 
        date of the enactment of this Act, the Inspector General of the 
        Department of Justice shall submit to Congress a report in 
        accordance with this subsection.
            (2) Content of report.--The report under paragraph (1) 
        shall include--
                    (A) a description of the status of Department of 
                Justice investigations of alleged violations of section 
                3261 of title 18, United States Code, to have been 
                committed by contract personnel, which shall include--
                            (i) the number of complaints received by 
                        the Department of Justice;
                            (ii) the number of investigations into 
                        complaints opened by the Department of Justice;
                            (iii) the number of criminal cases opened 
                        by the Department of Justice; and
                            (iv) the number and result of criminal 
                        cases closed by the Department of Justice; and
                    (B) findings and recommendations about the number 
                of criminal cases prosecuted by the Department of 
                Justice involving violations of section 3261 of title 
                18, United States Code.
            (3) Format of report.--The report under paragraph (1) shall 
        be submitted in unclassified format, but may contain a 
        classified annex as appropriate.

SEC. 3. FEDERAL BUREAU OF INVESTIGATION INVESTIGATIVE UNIT FOR 
              CONTINGENCY OPERATIONS.

    (a) Establishment of Theater Investigative Unit.--The Director of 
the Federal Bureau of Investigation shall ensure that there are 
adequate personnel through the creation of Theater Investigative Units 
to investigate allegations of criminal violations of section 3261 of 
title 18, United States Code, by contract personnel.
    (b) Responsibilities of Theater Investigative Unit.--The Theater 
Investigative Unit established for a theater of operations shall--
            (1) investigate reports that raise reasonable suspicion of 
        criminal misconduct by contract personnel;
            (2) investigate reports of fatalities resulting from the 
        use of force by contract personnel; and
            (3) upon conclusion of an investigation of alleged criminal 
        misconduct, refer the case to the Attorney General of the 
        United States for further action, as appropriate in the 
        discretion of the Attorney General.
    (c) Responsibilities of Federal Bureau of Investigation.--
            (1) Resources.--The Director of the Federal Bureau of 
        Investigation shall ensure that each Theater Investigative Unit 
        has adequate resources and personnel to carry out its 
        responsibilities.
            (2) Notification.--The Director of the Federal Bureau of 
        Investigation shall notify Congress whenever a Theater 
        Investigative Unit is established or terminated in accordance 
        with this section.
    (d) Responsibilities of Other Federal Agencies.--An agency 
operating in an area, or in close proximity to an area (as designated 
by the Department of Defense), where the Armed Forces is conducting a 
contingency operation shall cooperate with and support the activities 
of the Theater Investigative Unit. Any investigation carried out by the 
Inspector General of an agency shall be coordinated with the activities 
of the Theater Investigative Unit as appropriate.

SEC. 4. DEFINITIONS.

    In this Act:
            (1) Covered contract.--The term ``covered contract'' means 
        an agreement--
                    (A) that is--
                            (i) a prime contract awarded by an agency;
                            (ii) a subcontract at any tier under any 
                        prime contract awarded by an agency; or
                            (iii) a task order issued under a task or 
                        delivery order contract entered into by an 
                        agency; and
                    (B) according to which the work under such 
                contract, subcontract, or task order is carried out in 
                a region outside the United States in which the Armed 
                Forces are conducting a contingency operation.
            (2) Agency.--The term ``agency'' has the meaning given the 
        term ``Executive agency'' in section 105 of title 5, United 
        States Code.
            (3) Contingency operation.--The term ``contingency 
        operation'' has the meaning given the term section 101(13) of 
        title 10, United States Code.
            (4) Contractor.--The term ``contractor'' means an entity 
        performing a covered contract.
            (5) Contract personnel.--The term ``contract personnel'' 
        means persons assigned by a contractor (including 
        subcontractors at any tier) to perform work under a covered 
        contract.

SEC. 5. EFFECTIVE DATE.

    (a) Applicability.--The provisions of this Act shall apply to all 
covered contracts and all covered contract personnel in which the work 
under the contract is carried out in an area, or in close proximity to 
an area (as designated by the Department of Defense), where the Armed 
Forces is conducting a contingency operation on or after the date of 
the enactment of this Act.
    (b) Immediate Effectiveness.--The provisions of this Act shall 
enter into effect immediately upon the enactment of this Act.
    (c) Implementation.--With respect to covered contracts and covered 
contract personnel discussed in subsection (a)(1), the Director of the 
Federal Bureau of Investigation, and the head of any other agency to 
which this Act applies, shall have 90 days after the date of the 
enactment of this Act to ensure compliance with the provisions of this 
Act.

A: Security Contractor Accountability Act of 2007 - Provides that persons who, while employed under a federal agency contract in or in close proximity to an area where the Armed Forces are conducting a contingency operation, engage in conduct that would constitute an offense punishable by imprisonment for more than one year if engaged in within U.S. jurisdiction shall be punished as provided for that offense.

Requires the Inspector General of the Department of Justice (DOJ) to report to Congress on the status of the Department's investigations of violations alleged to have been committed by contract personnel and findings and recommendations about the Department's capacity and effectiveness in prosecuting misconduct by contract personnel.

Requires the Director of the Federal Bureau of Investigation (FBI) to ensure, through the creation of Theater Investigative Units, that there are adequate personnel to investigate allegations of criminal violations by contract personnel.
****
Q: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Generic Complex Drugs Safety and 
Effectiveness for Patients Act of 2015''.

SEC. 2. GAO STUDY OF SCIENTIFIC ISSUES REGARDING THE CURRENT REGULATORY 
              PATHWAY FOR REVIEWING GENERIC VERSIONS OF CERTAIN COMPLEX 
              DRUG PRODUCTS.

    (a) Study by GAO.--The Comptroller General of the United States 
shall conduct a study to determine the following:
            (1) With respect to nonbiologic complex drug products that 
        have not been fully characterized (as defined in subsection 
        (e)(1)), whether the listing of such drugs as reference 
        products in generic drug applications presents unique 
        challenges in meeting approval standards that are significantly 
        different than the challenges presented by generic drug 
        applications that list small-molecule reference products.
            (2) With respect to biological products that are within the 
        scope of the exception under section 7002(e)(2) of Public Law 
        111-148 (relating to temporary authority for the approval of 
        biological products under section 505 of the Federal Food, 
        Drug, and Cosmetic Act (21 U.S.C. 355)), whether the listing of 
        such biological products as reference products in generic drug 
        applications presents unique challenges in meeting approval 
        standards that are significantly different than the challenges 
        presented by generic drug applications that list small-molecule 
        reference products.
            (3) If the answer to the question under paragraph (1) or 
        (2) is that significantly different challenges are presented 
        for patients when reference products are nonbiologic complex 
        drug products that have not been fully characterized or when 
        reference products are biological products that are within the 
        scope of the exception under section 7002(e)(2) of Public Law 
        111-148:
                    (A) What degree of characterization of the proposed 
                generic version and the reference product should be 
                required in order to determine the safety and 
                effectiveness of the generic version.
                    (B) What degree of similarity should be required to 
                deem that the active ingredient of the proposed generic 
                version is the same as the active ingredient of the 
                reference product.
                    (C) What types of evidence should be required to 
                demonstrate that the proposed generic version is 
                bioequivalent to the reference product.
                    (D) What requirements should be established with 
                respect to the comparability of the manufacturing 
                process for the proposed generic version and the 
                manufacturing process for the reference product.
                    (E) Whether and to what extent clinical evidence is 
                needed to demonstrate that there is no difference in 
                immunogenicity between the proposed generic version and 
                the reference product.
                    (F) Whether and to what extent other clinical 
                evidence is needed to demonstrate that the proposed 
                generic version is as safe and effective for patients 
                as the reference product.
                    (G) Taking into account the determinations made 
                regarding the issues listed in subparagraphs (A) 
                through (F):
                            (i) Whether section 505(j) of the Federal 
                        Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) 
                        should be amended to establish provisions that 
                        expressly address the approval of copy versions 
                        of nonbiologic complex drug products that have 
                        not been fully characterized, provisions that 
                        expressly address the approval of copy versions 
                        of biological products that are within the 
                        scope of the exception under section 7002(e)(2) 
                        of Public Law 111-148, or both.
                            (ii) Whether section 505(b)(2) of such Act 
                        (21 U.S.C. 355(b)(2)) should be so amended.
                            (iii) Whether such Act should otherwise be 
                        so amended.
                            (iv) Whether section 351 of the Public 
                        Health Service Act (42 U.S.C. 262) should be so 
                        amended.
                    (H) Taking into account the determinations made 
                regarding the issues listed in subparagraphs (A) 
                through (F), and taking into consideration all relevant 
                guidances, draft guidances, and other agency policy 
                documents--
                            (i) whether the Food and Drug 
                        Administration should develop and provide to 
                        the public a policy document that provides a 
                        comprehensive statement of general principles 
                        on the evidence that is necessary to obtain the 
                        approval of such Administration for proposed 
                        generic versions of reference products that are 
                        nonbiologic complex drug products that have not 
                        been fully characterized or that are biological 
                        products; and
                            (ii) if so, the date by which such 
                        Administration could reasonably be expected to 
                        issue such comprehensive policy document.
    (b) Consultation.--The Comptroller General shall conduct the study 
under subsection (a) in consultation with--
            (1) the Secretary of Health and Human Services, acting 
        through the Commissioner of Food and Drugs; and
            (2) appropriate public and private entities, including 
        patient advocacy organizations, professional medical 
        associations, hospital pharmacies, scientists of academic and 
        business organizations, and representatives of the regulated 
        industry.
    (c) Required Consideration.--In carrying out the study under 
subsection (a), the Comptroller General shall consider the following:
            (1) Published clinical reports of clinically meaningful 
        (including serious) adverse events of patients to--
                    (A) generic versions of the nonbiologic complex 
                drug products that have not been fully characterized;
                    (B) generic versions of biological products; and
                    (C) the reference products.
            (2) The specific criteria that have been used by the 
        Secretary to approve generic versions of nonbiologic complex 
        drug products that have not been fully characterized or generic 
        versions of biological products.
            (3) The specific criteria specified in guidances, draft 
        guidance, and other documents issued by the Secretary regarding 
        applications under section 351(k) of the Public Health Service 
        Act (42 U.S.C. 262(k)) for the licensing of biosimilar 
        biological products.
    (d) Optional Consideration.--In carrying out the study under 
subsection (a), the Comptroller General may under subsection (c) 
consider the following information from foreign countries:
            (1) Reports described in subsection (c)(1) from foreign 
        countries that are listed in clause (i) or (ii) of section 
        802(b)(1)(A) of the Federal Food, Drug, and Cosmetic Act (21 
        U.S.C. 382(b)(1)(A)) or are designated pursuant to section 
        802(b)(1)(B) of such Act (21 U.S.C. 382(b)(1)(B)).
            (2) The guidelines or recommendations of the pharmaceutical 
        regulatory agencies of foreign countries described in paragraph 
        (1) regarding any class of products that such an agency 
        regulates as a biosimilar biological product, but that has been 
        or could be approved as a generic drug in the United States.
            (3) Any instance where the Secretary or such foreign 
        regulatory agencies have, after approving a generic version (or 
        a foreign equivalent) of a nonbiologic complex drug product 
        that has not been fully characterized or a generic version (or 
        a foreign equivalent) of a biological product, sought a 
        clinical trial to confirm--
                    (A) the generic version (or foreign equivalent) is 
                therapeutically equivalent to the reference product (or 
                meets a similar standard, in the case of a foreign 
                regulatory agency); or
                    (B) the safety and effectiveness of the generic 
                version (or foreign equivalent).
    (e) Completion Date.--Not later than the expiration of the 2-year 
period beginning on the date of the enactment of this Act, the 
Comptroller General shall complete the study under subsection (a) and 
submit a report describing the findings and conclusions of the study to 
the Secretary, the Committee on Energy and Commerce of the House of 
Representatives, and the Committee on Health, Education, Labor, and 
Pensions of the Senate.
    (f) Definitions.--
            (1) Complex drug product not fully characterized.--For 
        purposes of this section, the terms ``complex drug product that 
        has not been fully characterized'' and ``complex drug products 
        that have not been fully characterized'', with respect to a 
        nonbiologic drug, means a drug for which--
                    (A) the active ingredient has molecular diversity;
                    (B) scientific analytic methodologies are unable to 
                fully identify the molecular structures and 
                physiochemical properties of the active ingredient; and
                    (C) the nature of the active ingredient is not 
                understood sufficiently to identity--
                            (i) all the molecular components of the 
                        drug that are involved in producing the 
                        therapeutic effect; and
                            (ii) the mechanisms of action that produce 
                        such effect.
            (2) Other definitions.--For purposes of this section:
                    (A) The term ``bioequivalent'', with respect to a 
                generic drug, has the meaning given such term in 
                section 505(j)(8)(B) of the Federal Food, Drug, and 
                Cosmetic Act (21 U.S.C. 355(j)(8)(B)).
                    (B) The term ``generic drug'' or ``generic 
                version'', with respect to the United States, means a 
                drug that is approved under section 505(j) of the 
                Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
                355(j)).
                    (C) The term ``generic drug application'' means an 
                abbreviated application for the approval of a new drug 
                under section 505(j) of the Federal Food, Drug, and 
                Cosmetic Act (21 U.S.C. 355(j)).
                    (D) The term ``proposed'', with respect to a 
                generic version, means subject to a generic drug 
                application that is pending before the Food and Drug 
                Administration.
                    (E) The term ``reference product'', with respect to 
                a generic drug, has the meaning given the term ``listed 
                drug'' in section 505(j) of the Federal Food, Drug, and 
                Cosmetic Act (21 U.S.C. 355(j)).
                    (F) The term ``Secretary'' means the Secretary of 
                Health and Human Services.

A:
Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015 This bill requires the Government Accountability Office (GAO) to study whether generic versions of certain complex drugs or certain biological drugs face significantly different challenges in meeting the approval standards of the Food and Drug Administration (FDA) than generic versions of small-molecule drugs. (Complex drugs and biological drugs can be composed of large molecules that are more difficult to fully characterize than small molecules, so it can be more difficult to demonstrate that generic versions of these drugs are the same as the brand name versions.) If the GAO determines that these generic drugs face significantly different challenges, then the GAO must also determine: (1) the evidence that should be required to demonstrate that one of these generic drugs is sufficiently similar to the brand name drug in safety, composition, and activity; (2) whether the Federal Food, Drug, and Cosmetic Act should be amended to address the approval of these generic drugs; and (3) whether the FDA should develop a policy document on the evidence that is necessary to obtain approval of these generic drugs.
****